MIPS Value Pathways (MVP): Advancing Cancer Care Quality
The ACC MVP contains multiple quality measures. Click on each quality measure below for more information.
MIPS #47 Advance Care PlanningMIPS #134 Depression ScreeningMIPS #143 Pain Intensity QuantifiedMIPS #144 Pain Care PlanMIPS # PIMSH2 Utilization of GCSF in Metastatic Colorectal CancerMIPS # PIMSH 13 Mutation Testing for Stage IV Lung Cancer Completed Prior to the Start of Targeted TherapyMIPS #453 Percentage of Patients Who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 14 Days of Life MIPS # 457 Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 daysMIPS #451 RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody TherapyMIPS #450 Appropriate Treatment for Patients with Stage I (T1c) - III HER2 Positive Breast CancerMIPS #452 Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal AntibodiesMIPS #104 Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate CancerMIPS # 462 Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation TherapyMIPS # 487 Screening for Social Drivers of Health